SOLUTN 1.770 +0.12 (+7.3%) OTHERS SOLUTION GROUP BERHAD ("SGB" or "THE COMPANY") APPROVAL OF FACILITY DESIGN PLAN AND LAYOUT BY NATIONAL PHARMACEUTICAL REGULATORY AGENCY, MINISTRY OF HEALTH ("NPRA") SOLUTION GROUP BERHAD
Type Announcement Subject OTHERS Description SOLUTION GROUP BERHAD ("SGB" or "THE COMPANY") APPROVAL OF FACILITY DESIGN PLAN AND LAYOUT BY NATIONAL PHARMACEUTICAL REGULATORY AGENCY, MINISTRY OF HEALTH ("NPRA") Reference is made to the announcement dated 25 November 2020 where it was stated that the Company had on 13 October 2020 submitted the facility design plan and layout of the vaccine fill and finish facility to NPRA for approval.
The Board of Director of SGB wishes to announce that NPRA had vide its letter dated 14 December 2020 (which was received on 17 December 2020) approved the said facility design plan and layout.
The Company will commence the establishment of the fill and finish facility after the receipt of the approval from shareholders of SGB on the proposed diversification of the existing business of SGB and its subsidiaries to include the pharmaceutical related business, at an extraordinary general meeting to be convened.
Read it again tentatively and u will get the answer u’re looking for. In short, I think this vaccine venture by YongTai will pay off once AstraZeneca gets approval within weeks.
is it just me or anyone else noticed the trading details are rather odd, as if the price is purposely being pressed down for accumulation, but at the same time whoever who is controlling it isn't letting it go down to 0.305 just now, it just went up to 0.315 after few buying from 0.310 despite the trading details showing that it was supposed to go to 0.305
i wonder how long the insiders are going to accumulate before letting the price go up
Miz Raya, i am a long term investor, not a day trader, so i do have holding power, plus my initial entry price was 0.16, then i collected more at 0.27 few days back, just that i am sharing what i observe from my ebroking app, and wondering if anyone else notice the pattern in the trading details section
Operator used up all their bullets with the big push from 13 sen to 40 sen. They are now in the midst of heavy accumulation before the next big push. Don't forget pp price was set at 36 sen and 40 sen. Guaranteed they will need to keep the private investors happy with a handsome return. Hold on tight to your shares. This one will climb to at least rm1.
This stock is totally operator controlled. Just make sure you enter at this price because operator is also collecting at this price. Just look at the buy sell queue will give you the picture. Whether can play contra or need to hold is up to operator timing when to push.
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
kentrade888
1,572 posts
Posted by kentrade888 > 2020-12-17 14:41 | Report Abuse
SOLUTN
1.770
+0.12 (+7.3%)
OTHERS SOLUTION GROUP BERHAD ("SGB" or "THE COMPANY") APPROVAL OF FACILITY DESIGN PLAN AND LAYOUT BY NATIONAL PHARMACEUTICAL REGULATORY AGENCY, MINISTRY OF HEALTH ("NPRA")
SOLUTION GROUP BERHAD
Type Announcement
Subject OTHERS
Description
SOLUTION GROUP BERHAD ("SGB" or "THE COMPANY") APPROVAL OF FACILITY DESIGN PLAN AND LAYOUT BY NATIONAL PHARMACEUTICAL REGULATORY AGENCY, MINISTRY OF HEALTH ("NPRA")
Reference is made to the announcement dated 25 November 2020 where it was stated that the Company had on 13 October 2020 submitted the facility design plan and layout of the vaccine fill and finish facility to NPRA for approval.
The Board of Director of SGB wishes to announce that NPRA had vide its letter dated 14 December 2020 (which was received on 17 December 2020) approved the said facility design plan and layout.
The Company will commence the establishment of the fill and finish facility after the receipt of the approval from shareholders of SGB on the proposed diversification of the existing business of SGB and its subsidiaries to include the pharmaceutical related business, at an extraordinary general meeting to be convened.
This announcement is dated 17 December 2020.